At San Diego-based CDMO and CRO Abzena, Geoffrey M Glass has stepped into the CEO role. Glass has served as Chairman of the ...

MSD, known as Merck & Co in the US and Canada, licensed rights to Lenvima in 2018 in a near-$6 billion deal aimed at ...

BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG), which is impaired in LGMD and causes muscle wasting, initially in the ...

The news on vaccines was not so good, as declining sales of shingles shot Shingrix in the US and China pegged back growth to ...

At ESMO this year, AstraZeneca presented final overall survival results from the MATTERHORN Phase III Trial for patients with ...

CSL's already depressed share price sank further on the news of the delay, which chairman Dr Brian McNamee said was related ...

Eli Lilly and tech giant NVIDIA have joined forces on an ambitious plan – building the most powerful AI-powered supercomputer ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ilya Burkov, global head of healthcare & life sciences ...

Beyond R&D, AI is transforming the way biopharma companies commercialise therapies and interact with healthcare providers and patients. In a marketplace increasingly driven by personalised experiences ...

The suit also accuses J&J of anticipating that the link between Tylenol and autism would be thrust into the spotlight by the ...

According to HIV therapy specialist ViiV, which is majority owned by GSK with Pfizer and Shionogi as shareholders, the UK ...

Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.